Navin Fluorine International Ltd

- Navin Fluorine targets to maintain an Operating EBITDA margin around 25% (between 23%-27%) for FY '26, striving for stability amid market uncertainties. - CDMO business aims for $100 million revenue by FY '27, supported equally by existing contracts, new MSAs, and base business. - The fluoro specialty project (INR540 crores capex) is ramping up, expected to reach 50%-55% utilization by end FY '26, contributing to earnings growth. - Capital expenditure guidance for FY '26 is INR 500-600 crores, supporting capacity expansion and cGMP4 commissioning. - Depreciation and finance costs are increasing due to recent capex but expected to stabilize/decrease as debt reduces. - Continued strategic partnerships (e.g., with Chemours) are expected to drive revenue in advanced materials, further boosting profits and EPS. - The company emphasizes disciplined project execution and expects gradual but consistent growth over the next 2 years.

- Navin Fluorine is working on 10 to 15 commercial or late-stage products in the CDMO vertical with growth potential. - A commercial order from a U.S. major is expected for delivery in FY '26, following a successful scale-up order delivered in Q4 FY '25. - Multiple inquiries for R32 capacity came much before the capacity became operational, indicating strong demand. - Discussions with global majors for strategic partnerships on new capacities are ongoing. - The initial production capacity for Opteon is sufficient to support several field trials to accelerate market adoption. - The partnership with Chemours is aimed at scaling production as adoption of two-phase immersion cooling liquids grows. - Overall, order inflow is robust across product lines and geographies, supporting growth targets into FY '26 and FY '27.

- No explicit mention of any new fundraising through debt or equity in the provided transcript. - The company emphasizes a strong financial position with a net debt-to-equity of 0.37 as of March 31, 2025. - Capex plans for FY '26 are guided between INR 500-600 crores, funded comfortably through the balance sheet and cash flows. - Interest costs are expected to reduce as debt is paid down, indicating no immediate need for more borrowing. - The $14 million capex for the Chemours tie-up includes a $5 million contribution by Chemours themselves, reflecting a partnership rather than Navin alone funding. - Management underscores disciplined capital investments within a well-defined financial structure and strong balance sheet.

- Fluoro Specialty Project: Commercial production started Dec 2024 at Dahej facility; ramping up well. - Surat Expansion: INR 30 crores expansion initiated dispatches from Feb 2025. - cGMP4 Capex: INR 288 crores planned; Phase 1 (INR 160 crores) on track for commissioning by Q3 FY '26. - Opteon Project with Chemours: $14 million capex; initial capacity set up to accelerate market adoption, with potential for further capacity expansion. - CDMO Business: Strategic investment with capex run rate approx. INR 500-600 crores for FY '26. - Margins targeted at around 25% with ongoing efforts. - Partnership Importance: Chemours' $5 million co-investment symbolic for partnership and strategy, despite Navin's capacity to fully fund. - Growth Focus: Continuing targeted capital investments aligned with market evolution and strategic priorities. Overall, investments focus on capacity ramp-up, new technologies (advanced materials like immersion cooling liquids), and scaling CDMO capabilities.

- Navin Fluorine aims to grow its CDMO business to $100 million revenue by FY '27, supported equally by existing contracts, new MSAs, and base business. - The company sees strong growth in the liquid cooling market, expected to grow from $0.5 billion today to $3 billion by 2035, including two-phase immersion cooling liquids. - Fluoro specialty project (INR 540 crores capex) is ramping up with 50-55% utilization expected by end FY '26, contributing to revenue growth. - New capacity for R32 refrigerant is servicing global markets, with healthy pricing and strategic partnerships in discussion. - cGMP4 phase 1 capex (INR 160 crores) for CDMO business is on track for end of Q3 FY '26 commissioning, enabling further capacity expansion. - Overall revenue growth driven by product diversification, capacity expansions, and increasing repeat orders in CDMO and specialty chemicals.